These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 20424222)

  • 1. Glycemic control and cardiovascular disease in 7,454 patients with type 1 diabetes: an observational study from the Swedish National Diabetes Register (NDR).
    Eeg-Olofsson K; Cederholm J; Nilsson PM; Zethelius B; Svensson AM; Gudbjörnsdóttir S; Eliasson B
    Diabetes Care; 2010 Jul; 33(7):1640-6. PubMed ID: 20424222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New aspects of HbA1c as a risk factor for cardiovascular diseases in type 2 diabetes: an observational study from the Swedish National Diabetes Register (NDR).
    Eeg-Olofsson K; Cederholm J; Nilsson PM; Zethelius B; Svensson AM; Gudbjörnsdóttir S; Eliasson B
    J Intern Med; 2010 Nov; 268(5):471-82. PubMed ID: 20804517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Level of physical activity associated with risk of cardiovascular diseases and mortality in patients with type-2 diabetes: report from the Swedish National Diabetes Register.
    Zethelius B; Gudbjörnsdottir S; Eliasson B; Eeg-Olofsson K; Cederholm J;
    Eur J Prev Cardiol; 2014 Feb; 21(2):244-51. PubMed ID: 24227183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The triglycerides-to-HDL-cholesterol ratio and cardiovascular disease risk in obese patients with type 2 diabetes: an observational study from the Swedish National Diabetes Register (NDR).
    Eeg-Olofsson K; Gudbjörnsdottir S; Eliasson B; Zethelius B; Cederholm J;
    Diabetes Res Clin Pract; 2014 Oct; 106(1):136-44. PubMed ID: 25108897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pulse pressure strongly predicts cardiovascular disease risk in patients with type 2 diabetes from the Swedish National Diabetes Register (NDR).
    Nilsson PM; Cederholm J; Eeg-Olofsson K; Eliasson B; Zethelius B; Gudbjörnsdóttir S;
    Diabetes Metab; 2009 Dec; 35(6):439-46. PubMed ID: 19819740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LDL-cholesterol versus non-HDL-to-HDL-cholesterol ratio and risk for coronary heart disease in type 2 diabetes.
    Eliasson B; Gudbjörnsdottir S; Zethelius B; Eeg-Olofsson K; Cederholm J;
    Eur J Prev Cardiol; 2014 Nov; 21(11):1420-8. PubMed ID: 23774274
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Additive effects of glycaemia and dyslipidaemia on risk of cardiovascular diseases in type 2 diabetes: an observational study from the Swedish National Diabetes Register.
    Gudbjörnsdottir S; Eliasson B; Eeg-Olofsson K; Zethelius B; Cederholm J;
    Diabetologia; 2011 Oct; 54(10):2544-51. PubMed ID: 21674176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blood pressure and risk of cardiovascular diseases in type 2 diabetes: further findings from the Swedish National Diabetes Register (NDR-BP II).
    Cederholm J; Gudbjörnsdottir S; Eliasson B; Zethelius B; Eeg-Olofsson K; Nilsson PM;
    J Hypertens; 2012 Oct; 30(10):2020-30. PubMed ID: 22871895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association Between Use of Lipid-Lowering Therapy and Cardiovascular Diseases and Death in Individuals With Type 1 Diabetes.
    Hero C; Rawshani A; Svensson AM; Franzén S; Eliasson B; Eeg-Olofsson K; Gudbjörnsdottir S
    Diabetes Care; 2016 Jun; 39(6):996-1003. PubMed ID: 27208327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relative Prognostic Importance and Optimal Levels of Risk Factors for Mortality and Cardiovascular Outcomes in Type 1 Diabetes Mellitus.
    Rawshani A; Rawshani A; Sattar N; Franzén S; McGuire DK; Eliasson B; Svensson AM; Zethelius B; Miftaraj M; Rosengren A; Gudbjörnsdottir S
    Circulation; 2019 Apr; 139(16):1900-1912. PubMed ID: 30798638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lifetime and 10-year cardiovascular risk prediction in individuals with type 1 diabetes: The LIFE-T1D model.
    Helmink MAG; Hageman SHJ; Eliasson B; Sattar N; Visseren FLJ; Dorresteijn JAN; Harris K; Peters SAE; Woodward M; Szentkúti P; Højlund K; Henriksen JE; Sørensen HT; Serné EH; van Sloten TT; Thomsen RW; Westerink J
    Diabetes Obes Metab; 2024 Jun; 26(6):2229-2238. PubMed ID: 38456579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A1C variability predicts incident cardiovascular events, microalbuminuria, and overt diabetic nephropathy in patients with type 1 diabetes.
    Wadén J; Forsblom C; Thorn LM; Gordin D; Saraheimo M; Groop PH;
    Diabetes; 2009 Nov; 58(11):2649-55. PubMed ID: 19651819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk factors for atrial fibrillation in type 2 diabetes: report from the Swedish National Diabetes Register (NDR).
    Zethelius B; Gudbjörnsdottir S; Eliasson B; Eeg-Olofsson K; Svensson AM; Cederholm J
    Diabetologia; 2015 Oct; 58(10):2259-68. PubMed ID: 26088442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Independent contribution of A1C, systolic blood pressure, and LDL cholesterol control to risk of cardiovascular disease hospitalizations in type 2 diabetes: an observational cohort study.
    Nichols GA; Joshua-Gotlib S; Parasuraman S
    J Gen Intern Med; 2013 May; 28(5):691-7. PubMed ID: 23345072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new model for 5-year risk of cardiovascular disease in Type 1 diabetes; from the Swedish National Diabetes Register (NDR).
    Cederholm J; Eeg-Olofsson K; Eliasson B; Zethelius B; Gudbjörnsdottir S;
    Diabet Med; 2011 Oct; 28(10):1213-20. PubMed ID: 21627687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of First Cardiovascular Disease Event in Type 1 Diabetes Mellitus: The Steno Type 1 Risk Engine.
    Vistisen D; Andersen GS; Hansen CS; Hulman A; Henriksen JE; Bech-Nielsen H; Jørgensen ME
    Circulation; 2016 Mar; 133(11):1058-66. PubMed ID: 26888765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glycemic control and excess mortality in type 1 diabetes.
    Lind M; Svensson AM; Kosiborod M; Gudbjörnsdottir S; Pivodic A; Wedel H; Dahlqvist S; Clements M; Rosengren A
    N Engl J Med; 2014 Nov; 371(21):1972-82. PubMed ID: 25409370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical usefulness of different lipid measures for prediction of coronary heart disease in type 2 diabetes: a report from the Swedish National Diabetes Register.
    Eliasson B; Cederholm J; Eeg-Olofsson K; Svensson AM; Zethelius B; Gudbjörnsdottir S;
    Diabetes Care; 2011 Sep; 34(9):2095-100. PubMed ID: 21775750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preventable major cardiovascular events associated with uncontrolled glucose, blood pressure, and lipids and active smoking in adults with diabetes with and without cardiovascular disease: a contemporary analysis.
    Vazquez-Benitez G; Desai JR; Xu S; Goodrich GK; Schroeder EB; Nichols GA; Segal J; Butler MG; Karter AJ; Steiner JF; Newton KM; Morales LS; Pathak RD; Thomas A; Reynolds K; Kirchner HL; Waitzfelder B; Elston Lafata J; Adibhatla R; Xu Z; O'Connor PJ
    Diabetes Care; 2015 May; 38(5):905-12. PubMed ID: 25710922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Considerably decreased risk of cardiovascular disease with combined reductions in HbA1c, blood pressure and blood lipids in type 2 diabetes: Report from the Swedish National Diabetes Register.
    Eeg-Olofsson K; Zethelius B; Gudbjörnsdottir S; Eliasson B; Svensson AM; Cederholm J
    Diab Vasc Dis Res; 2016 Jul; 13(4):268-77. PubMed ID: 27190080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.